These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2695186)

  • 41. Time-dose factors in chemotherapy: expanding the concept of dose-intensity.
    Dembo AJ
    J Clin Oncol; 1987 May; 5(5):694-6. PubMed ID: 3572462
    [No Abstract]   [Full Text] [Related]  

  • 42. Mathematical models in high-dose chemotherapy.
    Souhami RL; Gregory WM; Birkhead BG
    Antibiot Chemother (1971); 1988; 41():21-8. PubMed ID: 3245689
    [No Abstract]   [Full Text] [Related]  

  • 43. Keeping an open mind about the doses of chemotherapy.
    Gelman RS
    J Natl Cancer Inst; 1990 Sep; 82(18):1446-7. PubMed ID: 2391714
    [No Abstract]   [Full Text] [Related]  

  • 44. Possible approaches to selective toxicity: new concepts in cancer chemotherapy.
    Rall DP; Homan ER
    Cancer Chemother Rep; 1967 Sep; 51(5):247-51. PubMed ID: 6062295
    [No Abstract]   [Full Text] [Related]  

  • 45. Chemotherapy-Induced Toxicities and their Impact on Daily Imaging Practice: Is this the Time to Reassess Our Imaging Interpretation?
    Scaglione M; Iacobellis F; Muto G; Basilico R
    Can Assoc Radiol J; 2023 May; 74(2):239-240. PubMed ID: 36113143
    [No Abstract]   [Full Text] [Related]  

  • 46. [Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity].
    Alberto P
    Bull Cancer; 1995; 82 Suppl 1():3s-8s. PubMed ID: 7626852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cytostatic chemotherapy in advanced age].
    Sauer H
    Geburtshilfe Frauenheilkd; 1995 Jan; 55(1):M1-5. PubMed ID: 7705590
    [No Abstract]   [Full Text] [Related]  

  • 48. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 49. [Dose factors/time factors in chemotherapy].
    Philip T; Bouffet E; Biron P; Brunat-Mentigny M
    Bull Cancer; 1989; 76(9):979-94. PubMed ID: 2695186
    [No Abstract]   [Full Text] [Related]  

  • 50. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas.
    Liem GS; Verweij J
    Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Segidrin: a new-type antineoplastic agent].
    Filov VA
    Vopr Onkol; 1994; 40(1-3):3-14. PubMed ID: 7701790
    [No Abstract]   [Full Text] [Related]  

  • 52. [Dose-effect of chemotherapy in bronchial small-cell cancer].
    de Crevoisier R; le Cesne A; le Chevalier T
    Rev Mal Respir; 1997 Sep; 14(4):269-75. PubMed ID: 9411610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of dose-dense chemotherapy in the management of breast cancer.
    Norton L
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.